A deadly meningitis outbreak last year drew attention to a relatively new segment of the drug industry: large-scale compounding pharmacies. The Food and Drug Administration is calling for new, stronger and clearer legislation to effectively oversee firms that mix custom drugs for specific patients. In the past two decades, compounding pharmacies have grown into a multimillion dollar business, making some of the highest risk drugs available. But they are not required to follow the safety rules that apply to commercial drug makers. State pharmacy boards have an uneven record of policing them. A panel joins Diane to discuss efforts to improve the safety and oversight of compounded drugs.